BCAX - CIK 0002023658
The table below shows Bicara Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | $33.00M | $24.80M | $34.30M | $15.90M | $15.80M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $12.74M |
| $7.70M |
| $7.22M |
| $7.46M |
| $4.76M |
| $3.91M |
| Operating income | -$60.24M | -$40.68M | -$32.02M | -$41.79M | -$20.63M | -$19.75M |
| Income tax | $52.00K | $40.00K | $52.00K | $72.00K | $0.00 | $0.00 |
| Net income | -$56.21M | -$36.33M | -$27.39M | -$36.85M | -$17.48M | -$17.05M |
| EPS (diluted) | -$0.93 | -$0.67 | -$0.50 | -$0.68 | -$1.60 | -$19.01 |